Balincan USA, Inc.
BCNN · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | – |
| % Growth | 32.2% | -26.6% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | – |
| Gross Profit | $0 | $0 | $0 | – |
| % Margin | 38.5% | 39% | 40.9% | – |
| R&D Expenses | $0 | $0 | $0 | – |
| G&A Expenses | $0 | $0 | $0 | – |
| SG&A Expenses | $0 | $0 | $0 | – |
| Sales & Mktg Exp. | $0 | $0 | $0 | – |
| Other Operating Expenses | $0 | $0 | $0 | – |
| Operating Expenses | $0 | $0 | $0 | – |
| Operating Income | -$0 | -$0 | -$0 | – |
| % Margin | -20.7% | -113.5% | -5.5% | – |
| Other Income/Exp. Net | -$0 | $0 | -$0 | – |
| Pre-Tax Income | -$0 | $0 | -$0 | – |
| Tax Expense | $0 | $0 | $0 | – |
| Net Income | -$0 | $0 | -$0 | – |
| % Margin | -139.3% | 34.8% | -7.4% | – |
| EPS | -0.019 | 0.009 | -0.009 | – |
| % Growth | -308.8% | 196.8% | – | – |
| EPS Diluted | -0.019 | 0.009 | -0.009 | – |
| Weighted Avg Shares Out | 0 | 0 | 0 | – |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | – |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | – |
| Interest Expense | $0 | $0 | -$0 | – |
| Depreciation & Amortization | $0 | $0 | $0 | – |
| EBITDA | -$0 | -$0 | -$0 | – |
| % Margin | -20.7% | -113.5% | -5.5% | – |